Condolences to the family. Please be careful, everyone. "Sudden death “smacks of being cardiovascular in nature,” Scannell wrote, adding that the possibility of a temporary slowdown in heart rate after patients start treatment with Gilenya is part of the reason for a recommendation for monitoring in a doctor’s office after treatment begins."


Novartis Confirms Patient Died After Starting Gilenya Drug - Businessweek
www.businessweek.com
Novartis AG said a multiple sclerosis patient died on Nov. 23 after starting treatment with Gilenya, the first pill approved to treat the debilitating neurological disease.